developed a multi-parameter stratification tool that combined clinical factors (sex, BE length, and pathological evaluation) with previously identified epigenetic biomarkers (CDKN2A, RUNX3, and HPPI) (84). The gene discussed is RUNX3; the disease is Barrett esophagus.